Navigation Links
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Date:8/27/2007

hen used in combination with the chemotherapy drug, carboplatin. Ovarian cancer patients whose cancer initially responded to chemotherapy, but has since become resistant or refractory to traditional platinum treatments are eligible to participate.

There will be an additional 30 sites in the USA, of which 7 are now recruiting patients, and there are 4 sites open in Australia.

The total number of patients to be treated in this pivotal study is 470. The trial consists of two double blind treatment arms. Patients in one trial arm will receive weekly carboplatin and phenoxodiol. Patients in the other trial arm will also receive weekly carboplatin, but a placebo will be substituted for phenoxodiol. Neither patients, nor their doctors will know to which trial arm the patients are randomised.

A change from receiving carboplatin (or cisplatin) in the traditional dose pattern (every two to three weeks) to a weekly carboplatin regimen has been reported to provide a tumour response in some patients with recurrent ovarian cancer(1-3). Thus in addition to learning more about the safety and efficacy of phenoxodiol, researchers will learn more about the efficacy of weekly carboplatin.

The primary outcome of the trial is the assessment of the relative time it takes for the ovarian cancer to progress. An analysis of interim results will be possible after 95 patients have progressed with their disease.

The trial is being run under arrangements approved by the US Food and Drug Administration (FDA) known as a Special Protocol Assessment (SPA). This provides for the interim analysis of the data, which, if significant, can be used to support a request for grant of marketing approval.

The Chief Executive Officer of Marshall Edwards, Inc., Mr. Christopher Naughton, said the Phase III Ovature study was a significant milestone for the Company.

"Over the next 12 to 18 months we expect the interim results from this multi-national clinical trial which ma
'/>"/>

SOURCE Novogen Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
(Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed... -- DALLAS, November 10, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... Md., Nov. 9, 2010 Most makers of approved ... and meeting targets for postmarketing studies/clinical trials in a ... the U.S. Food and Drug Administration (FDA). ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) The study, based on ...
Cached Medicine Technology:Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 2Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 3Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 4Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 5Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 6Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 7Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 8Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 9FDA: Majority of Drug and Biological Product Makers Meeting Postmarketing Requirements and Commitments 2
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 ALS Ice Bucket Challenge ... and the Boston Red Sox honor Ice Bucket co-founders Pat Quinn and Pete Frates, ... $100,000 to further collaborative efforts among the ALS organizations to find treatments and cures ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ... to. , Instead of risking containment — or even destruction — of products, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby ... post that encourages the understanding and treatment of ankle sprains. A common sports ... remedies. This can be dangerous if the condition augments and causes more disruption. ...
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ( http://evermaya.com/ ), a ... line will be named for Madeline Stuart, an 18-year-old model from Brisbane, Australia. ... model with Down syndrome, gracing the front pages of publications across the world. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the innovative leader ... Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is a compilation ... the benefits of using medication management technologies . , Eldermark’s ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... 8 Brookdale Senior Living Inc. (NYSE: BKD ... disclosed public offering of 13,953,489 shares of common stock, at ... underwriters in the offering exercised in full their option to ... at the public offering price, resulting in net proceeds to ...
... CITY, June 8 Qqest Software Systems today announced that ... and attendance software, as well as the company,s Payroll Services. ... over 5,000 medical procedures each year. Prior to adopting Qqest,s ... manual time clock and paper time cards to track time. ...
... ("Scient,x" or the "Company") announced today that it has ... Corporation and an incremental equity investment by the Company,s ... equity package amounts to $12.5 million. Terms were ... CEO of Scient,x stated, "I am excited that Scient,x ...
... Year-Long Phase 2 Diabetes Study Results Presented at ADA Annual ... VIVUS, Inc. (Nasdaq: VVUS ), a biopharmaceutical ... obesity, diabetes and sexual health, today announced that data from ... with type 2 diabetes are being highlighted in an oral ...
... expert cautions, , MONDAY, June 8 (HealthDay News) -- New ... might cause their disease to relapse may be reassured by a ... women. , The study, in the June 8 issue of ... with multiple sclerosis (MS) who breast-fed exclusively for two months or ...
... strong among those in their 20s, study finds, , MONDAY, ... colorectal cancer rates in the United States in the past ... on the upswing among people younger than 50. , The ... now running annually at 2.8 percent and 2.2 percent among ...
Cached Medicine News:Health News:Brookdale Announces Completion of Follow-On Offering 2Health News:Brookdale Announces Completion of Follow-On Offering 3Health News:Brookdale Announces Completion of Follow-On Offering 4Health News:Brookdale Announces Completion of Follow-On Offering 5Health News:Colorado Gastroenterology Chooses Qqest's TimeForce, Payroll Services 2Health News:Scient'x Groupe, S.A. Announces Completion of Credit Facility and Incremental Capital Infusion 2Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 2Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 3Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 4Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 5Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 6Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 7Health News:Breast-feeding OK for Most Moms with MS 2Health News:Breast-feeding OK for Most Moms with MS 3Health News:Colorectal Cancer Rates Rising for Under 50 Set 2Health News:Colorectal Cancer Rates Rising for Under 50 Set 3
Test for AFP...
Test for AFP...
Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Medicine Products: